Can we help?
We’d love to bring our combined 50 years of drug hunting experience to assist you.
Al G. Dossetter gained his Ph.D. from Nottingham University and after postdoctoral research at Harvard University joined AstraZeneca. He has 13 years of experience in medicinal chemistry spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors, and GPCR targets), and diabetes (obesity, GPCR, and enzyme inhibitors). In 2012, he cofounded MedChemica Limited to use matched molecular pair analysis to accelerate medicinal chemistry. Al is an enthusiastic advocate for science and is frequently invited to present his research.
Can we help?
We’d love to bring our combined 50 years of drug hunting experience to assist you.
Al G. Dossetter gained his Ph.D. from Nottingham University and after postdoctoral research at Harvard University joined AstraZeneca. He has 13 years of experience in medicinal chemistry spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors, and GPCR targets), and diabetes (obesity, GPCR, and enzyme inhibitors). In 2012, he cofounded MedChemica Limited to use matched molecular pair analysis to accelerate medicinal chemistry. Al is an enthusiastic advocate for science and is frequently invited to present his research.
Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. Taking a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he cofounded MedChemica Ltd.. He has taught medicinal chemistry courses at the University of Manchester and AstraZeneca courses in the U.K., France, and India. He is a named inventor on 16 patents and coauthored more than 15 articles, book chapters, and a textbook. His interests are in developing data driven methods to support decision making and medicinal chemistry education.
Andrew G. Leach obtained his Ph.D. from the University of Cambridge and undertook postdoctoral research at UCLA, supported by the Fulbright scheme. He returned to the UK to join AstraZeneca as a computational chemist and worked in oncology, diabetes, and obesity. In 2012, he became one of the cofounders of MedChemica Limited and also joined Liverpool John Moores University as a lecturer in the School of Pharmacy and Biomolecular Sciences. His interests include all aspects of computation to support drug discovery and medicinal chemistry as well as the use of quantum mechanics to unravel interesting reaction mechanisms. He has published more the 70 articles, 5 book chapters and is a named inventor on 12 patents.
Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. Taking a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he cofounded MedChemica Ltd.. He has taught medicinal chemistry courses at the University of Manchester and AstraZeneca courses in the U.K., France, and India. He is a named inventor on 16 patents and coauthored more than 15 articles, book chapters, and a textbook. His interests are in developing data driven methods to support decision making and medicinal chemistry education.
Andrew G. Leach obtained his Ph.D. from the University of Cambridge and undertook postdoctoral research at UCLA, supported by the Fulbright scheme. He returned to the UK to join AstraZeneca as a computational chemist and worked in oncology, diabetes, and obesity. In 2012, he became one of the cofounders of MedChemica Limited and also joined Liverpool John Moores University as a lecturer in the School of Pharmacy and Biomolecular Sciences. His interests include all aspects of computation to support drug discovery and medicinal chemistry as well as the use of quantum mechanics to unravel interesting reaction mechanisms. He has published more the 70 articles, 5 book chapters and is a named inventor on 12 patents.